Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Sells 14,566 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMOGet Free Report) SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Thermo Fisher Scientific Trading Down 0.0 %

NYSE TMO opened at $550.82 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm’s fifty day moving average price is $533.33 and its 200 day moving average price is $514.38. The company has a market capitalization of $212.82 billion, a price-to-earnings ratio of 35.65, a price-to-earnings-growth ratio of 2.32 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $593.17.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the firm posted $5.40 EPS. The company’s revenue was down 4.9% on a year-over-year basis. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback program on Tuesday, November 14th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TMO. Halpern Financial Inc. grew its position in Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after purchasing an additional 40 shares during the last quarter. Northwest Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. Coppell Advisory Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $33,000. Live Oak Investment Partners acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $36,000. Finally, Tyler Stone Wealth Management acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $37,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on TMO. Wells Fargo & Company upgraded shares of Thermo Fisher Scientific from an “underweight” rating to an “equal weight” rating and set a $475.00 target price on the stock in a report on Wednesday, October 25th. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Citigroup increased their target price on shares of Thermo Fisher Scientific from $530.00 to $575.00 and gave the stock a “buy” rating in a report on Monday, December 11th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $596.00.

Get Our Latest Stock Analysis on TMO

Thermo Fisher Scientific Company Profile

(Get Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.